The COVID-19 pandemic has created logistical challenges for companies prompting them to increase stocks in a bid to mitigate the impact of potential disruptions.

GlobalData has conducted a survey to assess the trend of scenarios pharmaceutical companies are developing to respond to coronavirus-related disruptions.

An analysis of the survey revealed that a majority of the companies did not develop any scenarios in Q1 although they began to stock-up inventories in Q3.

Companies that increased stocks for active pharmaceutical ingredients (API), and intermediates exported/imported from certain key countries and regions jumped from 24% in Q1 to 35% in Q3.

Planning scenarios related to COVID-19 Outbreak Q1 vs Q3

Similarly, the companies that increased the inventories for finished dose products exported/imported from certain key countries and regions increased from 12% in Q1 to 21% in Q3.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Further, 43% of the companies did not develop any scenarios but expected the pandemic to cause disruptions in Q1. The figure dropped to 24% in Q3.

The percentage of companies that did not develop any scenarios and did not expect the pandemic to cause any disruptions largely remained the same dropping by one percentage point, from 21% in Q1 to 20%, in Q3.

The analysis is based on responses received from Pharmaceutical Trade and Supply Chain Survey conducted between 07 July and 30 July 2020.